COVID-19 preclinical drug development database

Submit your project

"The Academy's database maps the landscape of preclinical COVID-19 research in the UK. By submitting their projects to the database, preclinical researchers from academia and industry alike are doing their part to help identify and prioritise important preclinical COVID-19 research, to help build treatments and research tools for a COVID-19-resilient future."

Professor Michael Malim FRS FMedSci, Expert Group Chair and Professor of Infectious Diseases and Head of School of Immunology & Microbial Sciences, King's College London


Around the world researchers are driving forward research at an unprecedented pace to tackle the COVID-19 pandemic. We aim to provide a comprehensive overview of research into developing novel therapeutic targets, new molecular entities and repurposing existing medicines.

We welcome and encourage contributions of a range of types from both academia and industry. We are interested in collating information on two main types of research:

  • Preclinical drug discovery and development for COVID-19, covering all modalities, mechanisms of action and therapeutic targets.
  • Supporting technologies that will inform and support drug development, including the development of assays, cell models, animal models and specialist reagents.

By submitting a project to the database, you are giving permission for the Academy to publicly display all information that you submit on the COVID-19 preclinical drug development database. You do not need to fill in all available fields if you have concerns around confidentiality or intellectual property. The Academy’s privacy policy, which outlines how submitted data will be handled and stored, can be found at:

"As the pandemic matures and we prepare for the future, we look increasingly to preclinical researchers to develop therapies to fight COVID-19 and the SARS-CoV-2 virus in years to come. The database helps researchers and funders avoid duplication of effort and find useful collaborators and initiatives, like the LifeArc Advise & Connect service, to move us towards treatments for COVID-19 together faster."

Dr Melanie Lee CBE FMedSci, Expert Group Member and Chief Executive Officer, LifeArc

Read the letter from the Academy's President and Vice President, inviting researchers to contribute to this survey:

If you have any questions about the submission process or need to update your submission, please visit the FAQs section for further information or email [email protected]


Partner institutions/organisations

(if a consortium please give name of consortium)


Key Contact

Project Details

Type of project
Type of supporting technology (if applicable)
Therapeutic target
Phase of project
Modality (if can be disclosed)
Molecular/cellular target (if known or can be disclosed)

Further details

Relevant weblinks (eg. research groups, press releases etc.)


Are you looking for collaborations, or access to expertise, materials or methodologies, or are there any other challenges that you need support with?

May we contact you if we would like to follow-up for additional information or to connect you to relevant colleagues?